+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Asia-Pacific Dry Powdered Inhaler Market 2019-2025

  • PDF Icon

    Report

  • January 2020
  • Region: Asia Pacific
  • Orion Market Research Private Limited
  • ID: 4988036
UP TO OFF until Dec 31st 2022
Asia-Pacific Dry Powdered Inhaler Market Size, Share & Trends Analysis Report by Type (Preventive Inhaler, Reliever Inhaler, and Long-Acting Bronchodilators Inhaler), by Application (Asthma and Chronic Obstructive Pulmonary Disease (COPD)), by End-User (Homecare and Hospitals and Clinics) and Forecast 2019-2025.

Asia-Pacific dry powdered inhaler market is anticipated to grow at a substantial rate of around 4.0% during the forecast period. Major factors that augments the growth of the market include large population base susceptible to asthma and COPD, rising awareness about treatment for asthma and COPD, and significant presence of market players in the region. Asia-Pacific has a potential market due to the increasing R&D and investments by big pharmaceutical companies in life science research coupled with harnessing innovation. The dry powdered inhaler market in the Asia-Pacific region presents future opportunities for growth as the prevalence of respiratory diseases such as asthma, COPD in emerging economies such as India and China. In addition, increasing the geriatric population specially in Japan is another major reason for the growth of the market.

Asia-Pacific dry powdered inhaler market is segmented based on type, application, and end-user. Based on the type, preventive, reliever, and long-acting bronchodilators dry powdered inhalers are analyzed. The preventive dry powdered inhaler segment led the global dry powdered inhaler market in 2018. Preventive inhalers are most widely used in the treatment of asthma in children and adults. These inhalers do not entail side effects for long-term use, and exceptionally decreases the possibility of an asthma exacerbation. The preventive inhalers further reduce the airways swelling and hence, are recommended for regular use by the physician. Some of the preventive inhalers available in the market include Budesonide and Fluticasone. Moreover, based on the application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing dry powdered inhalers to cater to a wide range of customers within the region and across the globe. The major players of the Asia-Pacific dry powdered inhaler market include 3M Co., AstraZeneca PLC, Aradigm Corp., Adherium Ltd., GlaxoSmithKline PLC, Novartis AG, Propeller Health, Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players. For instance, in May 2018, the company established a partnership with MannKind for marketing and distributing Afrezza. It is the only US FDA approved inhaled insulin available for patients suffering from diabetes. In addition, the company in February 2018, has entered into a partnership with Roche Pharma India for healthcare improvement and increasing access to life-changing medicines in India.

Research Methodology

The market study of the Asia-Pacific dry powdered inhaler market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors.

Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for dry powdered inhaler manufacturers, contract research organizations (CROs), healthcare sector, market research firms, and government organizations, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation

1. Asia-Pacific Dry Powdered Inhaler Market Research and Analysis by Type
2. Asia-Pacific Dry Powdered Inhaler Market Research and Analysis by Application
3. Asia-Pacific Dry Powdered Inhaler Market Research and Analysis by End-User

The Report Covers
  • Comprehensive research methodology of the Asia-Pacific dry powdered inhaler market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Asia-Pacific dry powdered inhaler market.
  • Insights about market determinants which are stimulating the Asia-Pacific dry powdered inhaler market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Asia-Pacific Dry Powdered Inhaler Market by Type
5.1.1. Preventive Inhaler
5.1.2. Reliever Inhaler
5.1.3. Long Acting Bronchodilators Inhaler
5.2. Asia-Pacific Dry Powdered Inhaler Market by Application
5.2.1. Asthma
5.2.2. Chronic Obstructive Pulmonary Disease (COPD)
5.3. Asia-Pacific Dry Powdered Inhaler Market by End-User
5.3.1. Homecare
5.3.2. Hospitals and Clinics
6. Regional Analysis
6.1. China
6.2. Japan
6.3. India
6.4. Rest of Asia-Pacific
7. Company Profiles
7.1. 3M Co.
7.2. Acorda Therapeutics, Inc.
7.3. Adamis Pharmaceuticals Corp.
7.4. Adherium Ltd.
7.5. Aradigm Corp.
7.6. AstraZeneca PLC
7.7. Beximo Pharmaceuticals Ltd.
7.8. Boehringer Ingelheim International GmbH
7.9. Cipla Ltd.
7.10. GlaxoSmithKline PLC
7.11. Koninklijke Philips N.V.
7.12. MidasCare Pharmaceutical Pvt. Ltd.
7.13. Novartis AG
7.14. Omron Healthcare Inc.
7.15. ResMed Corp.
7.16. Sunovion Pharmaceuticals
7.17. Teijin Pharma Ltd.
7.18. Teva Pharmaceuticals Industries Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 3M Co.
  • Acorda Therapeutics, Inc.
  • Adamis Pharmaceuticals Corp.
  • Adherium Ltd.
  • Aradigm Corp.
  • AstraZeneca PLC
  • Beximo Pharmaceuticals Ltd.
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • GlaxoSmithKline PLC
  • Koninklijke Philips N.V.
  • MidasCare Pharmaceutical Pvt. Ltd.
  • Novartis AG
  • Omron Healthcare Inc.
  • ResMed Corp.
  • Sunovion Pharmaceuticals
  • Teijin Pharma Ltd.
  • Teva Pharmaceuticals Industries Ltd.